Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04175613 · ClinicalTrials.gov registry record · Phase 3
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT04175613 is a Phase 3 study of Psoriasis that has completed, run by Amgen. The registered enrollment target is 160 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04175613, a Phase 3 study of Psoriasis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy. The study will consist of up to 208 weeks of long-term treatment followed by an 8-week observational follow-up phase.
Conditions Studied
Interventions
- DRUG Apremilast
Study Locations (20)
California
- First OC Dermatology - Irvine
- Stanford University School of Medicine - Palo Alto
- California Dermatology Institute - Thousand Oaks
Other
- Centre Hospitalier Universitaire Saint Pierre - Brussels
- Cliniques Universitaires Saint Luc - Brussels
- Universitair Ziekenhuis Gent - Ghent
Florida
- Solutions Through Advanced Research Inc - Jacksonville
- Ciocca Dermatology - Miami
Arizona
- Phoenix Childrens Hospital - Phoenix
Arkansas
- Johnson Dermatology Clinic - Fort Smith
Georgia
- Skin Care Physicians of Georgia - Macon
Indiana
- Dawes Fretzin Dermatology Group Inc - Indianapolis
Ohio
- Wright State Physicians - Fairborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2025-12-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04175613
The ClinicalTrials.gov registry entry for NCT04175613 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (67% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Apremilast is the first listed.
NCT04175613 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT04175613 about?
NCT04175613 is a clinical study titled "A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis". This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy. The study will consist of up to 208 weeks of long-term treatment followed by an 8-week observational follow...
What is the current status of trial NCT04175613?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2019-12-20. Estimated completion is 2025-12-12.
What conditions does trial NCT04175613 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT04175613?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT04175613?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04175613 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.